Generic Name and Formulations:
Hyoscyamine sulfate 0.125mg; sublingual scored tabs; peppermint flavor; dye-free.
- Specific T Cells Play Key Role in Melanoma-Immune Equilibrium
- Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019
- Statins Repurposed to Slow Proliferation in Metastatic Breast Cancer Cells
- Irritable Bowel Syndrome (IBS) Treatments
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Pharmacokinetics of Atypical Antipsychotics
Indications for LEVSIN/SL:
Adjunct in peptic ulcer. Irritable bowel syndrome. Infant colic.
1–2 tabs sublingually, swallowed, or chewed every 4 hrs or as needed; max 12 tabs/day.
<2yrs: not recommended. ≥2yrs: ½ –1 tab sublingually, swallowed, or chewed every 4 hrs or as needed; max 6 tabs/day.
Glaucoma. Unstable cardiovascular status in acute hemorrhage. GI or urinary tract obstruction. Paralytic ileus, intestinal atony of elderly or debilitated patients. Toxic megacolon. Severe ulcerative colitis. Myasthenia gravis.
High environmental temperature. Diarrhea. Autonomic neuropathy. Impaired cardiac or renal function. Cardiovascular disease. Hypertension. Hyperthyroidism. Hiatal hernia with reflux esophagitis. Pregnancy (Cat.C). Nursing mothers.
Antacids may inhibit absorption. Additive anticholinergic effects with other anticholinergics, amantadine, type I antiarrhythmics, antihistamines, phenothiazines, tricyclics, MAOIs.
Anticholinergic effects, drowsiness.
Formerly known under the brand name Levsin Drops.
Tabs, SL—100, 500; Drops—contact supplier
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Ketogenic Diet as an Adjunct to Cancer Treatment
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Blinatumomab-Ponatinib Salvage Therapy in B-Cell Acute Lymphoblastic Leukemia: Case Report of Benefit
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer